A Phase 3 interventional study of LUM/IVA and LUM/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 61 sites in 9 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2021-05-24.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 5th largest by enrollment, is one of 3 that started in 2015, is one of 10 in phase 3, and was the 14th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →
lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2015.
This study's enrollment of 246 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 66 across the 20 interventional studies. Of the 20 that completed or were terminated, 15 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 1 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 20th largest by enrollment of the 116 interventional ones that give a count, is one of 12 that started in 2015, is one of 62 in phase 3, and was the 45th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
Study 110 is a Phase 3, multicenter study in subjects aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation and who participated in Study 109 (NCT02514473) or Study 011B (NCT01897233). Study 110 is designed to evaluate the safety and efficacy of long term treatment of lumacaftor in combination with ivacaftor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects entering the Treatment Cohort must meet both of the following criteria:
Subjects entering the Observational Cohort must meet 1 of the following criteria:
Exclusion Criteria (Treatment Cohort Only):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LUM/IVA
Drug: LUM/IVA
Drug: LUM/IVA
Drug pages: Lumacaftor · Ivacaftor
Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age). LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older).
Also known as: VX-809/VX-770, lumacaftor/ivacaftor
Drug pages: Lumacaftor · Ivacaftor
LUM 200 mg q12h/IVA 250 mg q12h (for 6 through 11 years of age).
Also known as: VX-809/VX-770, lumacaftor/ivacaftor
Treatment Period 1 (Treatment Cohorts): Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Week 100
Absolute Change in Lung Clearance Index (LCI) 2.5
LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.
Time frame: From Parent Study Baseline at Week 96
Absolute Change in Sweat Chloride
Sweat samples were collected using an approved collection device.
Time frame: From Parent Study Baseline at Week 96
Absolute Change in Body Mass Index (BMI)
BMI was defined as weight in kilograms divided by height in square meter (m\^2).
Time frame: From Parent Study Baseline at Week 96
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: From Parent Study Baseline at Week 96
Observational Cohort: Safety as Assessed by Serious Adverse Events (SAEs)
Time frame: Day 1 up to Week 100
Absolute Change in LCI 5.0
LCI 5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.
Time frame: From Parent Study Baseline at Week 96
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Parent Study Baseline at Week 96
Relative Change in ppFEV1
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Parent Study Baseline at Week 96
Absolute Change in BMI-for-age Z-score
BMI was defined as weight in kilograms divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
Time frame: From Parent Study Baseline at Week 96
Absolute Change in Weight
Time frame: From Parent Study Baseline at Week 96
Absolute Change in Weight-for-age Z-score
z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
Time frame: From Parent Study Baseline at Week 96
Absolute Change in Height
Time frame: From Parent Study Baseline at Week 96
Absolute Change in Height-for-age Z-score
z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
Time frame: From Parent Study Baseline at Week 96
Absolute Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Total Domain Score
The TSQM measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed in the total domain score, which ranges from 0 to 100, where higher scores indicate greater satisfaction.
Time frame: From Parent Study Baseline at Week 96
Time-to-first Pulmonary Exacerbation
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
Time frame: From Parent Study Baseline through Week 96
Percentage of Participants Having At Least 1 Pulmonary Exacerbation Event
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
Time frame: From Parent Study Baseline through Week 96
Number of Pulmonary Exacerbation Events Per Patient-year
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
Time frame: From Parent Study Baseline through Week 96
Rate of Change in LCI 2.5
Rate of change analysis evaluates the change in LCI 2.5 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.
Time frame: Day 15 after first dose of LUM/IVA through Week 96
Rate of Change in LCI 5.0
Rate of change analysis evaluates the change in LCI 5.0 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.
Time frame: Day 15 after first dose of LUM/IVA through Week 96
Rate of Change in ppFEV1
Rate of change analysis evaluates the change in ppFEV1 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.
Time frame: Day 15 after first dose of LUM/IVA through Week 96
Treatment Period 2: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Week 168
This study consists of 2 Treatment Periods: Treatment Period 1 and Treatment Period 2. Treatment Period 1 had Treatment Cohorts and an Observational Cohort.
| Milestone | Treatment Period 1: LUM/IVA to LUM/IVA | Treatment Period 1: PBO to LUM/IVA | Treatment Period 1: Observational Cohort | Treatment Period 2: LUM/IVA |
|---|---|---|---|---|
| Started | 143 | 96 | 6 | 0 |
| Completed | 129 | 84 | 5 | 0 |
| Not completed | 14 | 12 | 1 | 0 |
| Withdrew: Adverse event | 1 | 6 | 0 | 0 |
| Withdrew: Withdrawal of consent (not due to ae) | 3 | 2 | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 |
| Withdrew: Physician decision | 4 | 0 | 0 | 0 |
| Withdrew: Other | 4 | 4 | 0 | 0 |
| Milestone | Treatment Period 1: LUM/IVA to LUM/IVA | Treatment Period 1: PBO to LUM/IVA | Treatment Period 1: Observational Cohort | Treatment Period 2: LUM/IVA |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 10 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 10 |
| Withdrew: Commercial drug is available for subject | 0 | 0 | 0 | 10 |
| participants | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Participants with any AEs | 142 | 94 |
| Participants with SAEs | 43 | 29 |
LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.
| lung clearance index | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Absolute Change in Lung Clearance Index (LCI) 2.5 | -0.85 (-1.25 to -0.45) | -0.86 (-1.33 to -0.38) |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Absolute Change in Sweat Chloride | -22.9 (-25.5 to -20.3) | -22.8 (-26.3 to -19.3) |
BMI was defined as weight in kilograms divided by height in square meter (m\^2).
| kg/m^2 | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Absolute Change in Body Mass Index (BMI) | 1.78 (1.56 to 1.99) | 2.04 (1.77 to 2.31) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score | 7.4 (4.8 to 10.0) | 6.6 (3.1 to 10.0) |
| participants | Observational Cohort |
|---|---|
| Observational Cohort: Safety as Assessed by Serious Adverse Events (SAEs) | 1 |
LCI 5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.
| lung clearance index | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Absolute Change in LCI 5.0 | -0.21 (-0.36 to -0.06) | -0.31 (-0.49 to -0.13) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent predicted of FEV1 | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | 3.1 (1.0 to 5.1) | 0.0 (-2.7 to 2.7) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent change | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Relative Change in ppFEV1 | 4.9 (2.2 to 7.5) | 0.5 (-2.9 to 4.0) |
BMI was defined as weight in kilograms divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
| z-score | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Absolute Change in BMI-for-age Z-score | 0.17 (0.08 to 0.26) | 0.31 (0.19 to 0.42) |
| kg | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Absolute Change in Weight | 10.3 (9.6 to 11.0) | 11.0 (10.1 to 11.8) |
z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
| z-score | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Absolute Change in Weight-for-age Z-score | 0.12 (0.04 to 0.20) | 0.24 (0.14 to 0.34) |
| centimeter (cm) | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Absolute Change in Height | 13.4 (12.9 to 14.0) | 13.5 (12.8 to 14.1) |
z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
| z-score | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Absolute Change in Height-for-age Z-score | -0.01 (-0.08 to 0.07) | 0.02 (-0.07 to 0.11) |
The TSQM measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed in the total domain score, which ranges from 0 to 100, where higher scores indicate greater satisfaction.
| units on a scale | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Absolute Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Total Domain Score | 5.1 (1.7 to 8.4) | 3.9 (-0.6 to 8.5) |
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
| days | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Time-to-first Pulmonary Exacerbation | 720.00 (278.00 to NA) | NA (513.00 to NA) |
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
| percentage of participants | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Percentage of Participants Having At Least 1 Pulmonary Exacerbation Event | 49.5 | 32.3 |
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
| events per patient-year | LUM/IVA to LUM/IVA | PBO to LUM/IVA |
|---|---|---|
| Number of Pulmonary Exacerbation Events Per Patient-year | 0.45 (0.33 to 0.61) | 0.30 (0.21 to 0.43) |
Rate of change analysis evaluates the change in LCI 2.5 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.
| slope | LUM/IVA Overall |
|---|---|
| Rate of Change in LCI 2.5 | -0.01 (-0.12 to 0.09) |
Rate of change analysis evaluates the change in LCI 5.0 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.
| slope | LUM/IVA Overall |
|---|---|
| Rate of Change in LCI 5.0 | 0.00 (-0.04 to 0.04) |
Rate of change analysis evaluates the change in ppFEV1 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.
| slope | LUM/IVA Overall |
|---|---|
| Rate of Change in ppFEV1 | 0.58 (0.02 to 1.14) |
| participants | Treatment Period 2: LUM/IVA |
|---|---|
| Participants with any AEs | 9 |
| Participants with SAEs | 0 |
Collected over Treatment Period 1: Day 1 up to Week 100, Treatment Period 2: Day 1 up to Week 168. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Period 1: LUM/IVA to LUM/IVA | 0/143 (0%) | 43/143 (30.1%) | 141/143 (98.6%) |
| Treatment Period 1: PBO to LUM/IVA | 0/96 (0%) | 29/96 (30.2%) | 93/96 (96.9%) |
| Treatment Period 1: Observational Cohort | 0/6 (0%) | 1/6 (16.7%) | — |
| Treatment Period 2: LUM/IVA | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Event | Treatment Period 1: LUM/IVA to LUM/IVA | Treatment Period 1: PBO to LUM/IVA | Treatment Period 1: Observational Cohort | Treatment Period 2: LUM/IVA |
|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 34/143 | 15/96 | 1/6 | 0/10 |
| ConstipationGastrointestinal disorders | 4/143 | 0/96 | 0/6 | 0/10 |
| Pulmonary function test decreasedInvestigations | 2/143 | 2/96 | 0/6 | 0/10 |
| Alanine aminotransferase increasedInvestigations | 0/143 | 2/96 | 0/6 | 0/10 |
| Aspartate aminotransferase increasedInvestigations | 0/143 | 2/96 | 0/6 | 0/10 |
| Bronchopulmonary aspergillosis allergicInfections and infestations | 2/143 | 0/96 | 0/6 | 0/10 |
| PneumoniaInfections and infestations | 1/143 | 1/96 | 0/6 | 0/10 |
| AppendicitisInfections and infestations | 0/143 | 1/96 | 0/6 | 0/10 |
| Gastroenteritis viralInfections and infestations | 0/143 | 1/96 | 0/6 | 0/10 |
| Viral upper respiratory tract infectionInfections and infestations | 0/143 | 1/96 | 0/6 | 0/10 |
| Event | Treatment Period 1: LUM/IVA to LUM/IVA | Treatment Period 1: PBO to LUM/IVA | Treatment Period 1: Observational Cohort | Treatment Period 2: LUM/IVA |
|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 91/143 | 64/96 | — | 2/10 |
| RhinitisInfections and infestations | 9/143 | 7/96 | — | 6/10 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 59/143 | 34/96 | — | 4/10 |
| PyrexiaGeneral disorders | 45/143 | 27/96 | — | 1/10 |
| NasopharyngitisInfections and infestations | 21/143 | 16/96 | — | 3/10 |
| HeadacheNervous system disorders | 29/143 | 26/96 | — | 1/10 |
| Upper respiratory tract infectionInfections and infestations | 36/143 | 13/96 | — | 0/10 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 34/143 | 21/96 | — | 0/10 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 32/143 | 18/96 | — | 0/10 |
| Alanine aminotransferase increasedInvestigations | 22/143 | 21/96 | — | 0/10 |
Treatment Cohort: All participants dosed in the parent studies and dosed in the current study. Observational Cohort: All participants enrolled in the observational cohort of the current study.
| Age, Customized(Participants) | LUM/IVA to LUM/IVA | PBO to LUM/IVA | Observational Cohort | Total |
|---|---|---|---|---|
| Less than 9 Years | 58 | 38 | 5 | 101 |
| Greater than or equal to 9 years | 85 | 58 | 1 | 144 |
| Sex: Female, Male(Participants) | LUM/IVA to LUM/IVA | PBO to LUM/IVA | Observational Cohort | Total |
|---|---|---|---|---|
| Female | 83 | 56 | 2 | 141 |
| Male | 60 | 40 | 4 | 104 |
| Ethnicity (NIH/OMB)(Participants) | LUM/IVA to LUM/IVA | PBO to LUM/IVA | Observational Cohort | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 0 | 4 |
| Not Hispanic or Latino | 139 | 93 | 6 | 238 |
| Unknown or Not Reported | 2 | 1 | 0 | 3 |
| Race (NIH/OMB)(Participants) | LUM/IVA to LUM/IVA | PBO to LUM/IVA | Observational Cohort | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 140 | 92 | 6 | 238 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 3 | 0 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2015 to primary completion in Aug 2018, 36 months.
Results were first posted in Oct 2019, 1 year 2 months after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 36 months is above that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lumacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →